I am a breastfeeding mother and i want to know if it is safe to use UNII-BZ114NVM5P? Is UNII-BZ114NVM5P safe for nursing mother and child? Does UNII-BZ114NVM5P extracts into breast milk? Does UNII-BZ114NVM5P has any long term or short term side effects on infants? Can UNII-BZ114NVM5P influence milk supply or can UNII-BZ114NVM5P decrease milk supply in lactating mothers?
- DrLact safety Score for UNII-BZ114NVM5P is 7 out of 8 which is considered Dangerous as per our analyses.
- A safety Score of 7 indicates that usage of UNII-BZ114NVM5P may cause toxic or severe side effects in breastfed baby.
- Our study of different scientific research indicates that UNII-BZ114NVM5P may cause moderate to high side effects or may affect milk supply in lactating mother.
- Our suggestion is to use safer alternate options rather than using UNII-BZ114NVM5P .
- Usage of UNII-BZ114NVM5P is in contradiction to breastfeeding hence if it is must to use UNII-BZ114NVM5P and there is no better alternative available then breastfeeding shall be stopped permanently or temporarily.
- Score calculated using the DrLact safety Version 1.2 model, this score ranges from 0 to 8 and measures overall safety of drug in lactation. Scores are primarily calculated using publicly available case studies, research papers, other scientific journals and publically available data.
Drug is cleared from the body in 3-5 elimination half-lives. Resuming breastfeeding is likely safe after 2 - 3 months of of pumping-and-dumping.
Most sources consider breastfeeding to be contraindicated during maternal antineoplastic drug therapy, such as UNII-BZ114NVM5P.[1][2] It might be possible to breastfeed safely during intermittent therapy with an appropriate period of breastfeeding abstinence, but the duration of abstinence is not clear. In one patient, UNII-BZ114NVM5P was still detectable in milk 28 days after a dose of 6 mg per square meter. Chemotherapy may adversely affect the normal microbiome and chemical makeup of breastmilk.[3] Women who receive chemotherapy during pregnancy are more likely to have difficulty nursing their infant.[4]
One mother received 3 daily doses of 6 mg/sq m of UNII-BZ114NVM5P intravenously along with 5 daily doses of etoposide 80 mg/sq m and cytarabine 170 mg/sq m intravenously. She resumed breastfeeding her infant 3 weeks after the third dose of UNII-BZ114NVM5P at a time when UNII-BZ114NVM5P was still detectable in milk. The infant had no apparent abnormalities at 16 months of age.[3]
Disclaimer:
Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. We do not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.